T-DXd vs CDK4/6i plus hormone therapy for advanced HR-positive, HER2-low breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial compares two treatments for advanced breast cancer that is HR-positive, HER2-low or ultralow, and a non-luminal subtype. It tests if a targeted antibody-drug conjugate (T-DXd) works better than the usual first-line therapy combining a CDK4/6 inhibitor with hormone therapy. This study is for people who have not had any treatment for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of breast cancer called HR-positive, HER2-low or HER2-ultralow, and a non-luminal subtype (determined by a special test).
- You have never received any chemotherapy, hormone therapy, or targeted therapy for breast cancer that has spread to other parts of the body.
- Your cancer either came back while you were on hormone therapy or within 1 year of finishing it, or if you were diagnosed with metastatic cancer from the start, you have certain features like a low estrogen receptor level, high tumor grade, high Ki67, liver metastases, or a non-luminal subtype.
- You are in generally good health (able to do daily activities) and your kidney, liver, and blood cell counts are within acceptable ranges.
- You have measurable tumors (not just in the bones) that can be seen on CT or MRI scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted drug combination for HER2-positive, hormone-receptor-positive breast cancer that has spread. It aims to shrink tumors and control the disease for as long as possible, with a planned switch to maintenance therapy after initial response.
This study looks at treatment choices for adults with breast cancer that has spread and cannot be removed by surgery (unresectable metastatic disease). It focuses on people with HER2-low (and some HER2-ultralow) and/or hormone-receptor positive cancer, and compares how well treatments like T-DXd or standard chemotherapy work.
This trial compares a targeted antibody-drug conjugate called T-DXd against standard hormone therapy for women with HR+, HER2-low advanced breast cancer that has progressed after first-line endocrine therapy plus a CDK4/6 inhibitor. It aims to see if T-DXd works better than continuing hormone therapy alone.
This study tests a drug called T-DXd (trastuzumab deruxtecan) for people with advanced breast cancer that has very low levels of HER2 (a protein that helps cancer grow) and that is also hormone receptor positive. The goal is to see if this drug can help shrink or slow the cancer.
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
This study is testing a drug called T-DXd (a targeted therapy) in people with advanced breast cancer that has HER2 overexpression or underexpression. It looks at how well the drug works in real-world settings, which may provide a new treatment option if your cancer has progressed.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.